Contribution of immunotherapy in the treatment of advanced biliary tract cancer

Apport de l'immunothérapie dans le traitement des cancers des voies biliaires avancés

Matthieu Delaye (1) , Astrid Lièvre (2, 3) , Cindy Neuzillet (1)

1 ICSC - Institut Curie - Saint Cloud
2 OSS - Oncogenesis, Stress, Signaling
3 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]

Contribution of immunotherapy in the treatment of advanced biliary tract cancer Biliary tract cancers (BTC) are rare tumors with a poor prognosis. Their treatment, at an advanced stage, relies on combinations of chemotherapies, which have a limited range and duration of benefit. Immunotherapy has emerged in recent years as a new therapeutic approach for BTC. However, the benefit with currently available treatments seems more modest than in other tumor locations and the predictive markers of response to these treatments remain to be identified. This review article summarizes the rationale, current data, and prospects and challenges for the development of immunotherapy in BTC.

Mots clés: Biliary tract cancer; Biomarkers; Immunotherapy

Mots clés: Biomarqueurs; Cancers des voies; Immunothérapie; biliaires

Domaines: Sciences du Vivant [q-bio]; Cancer; Hépatologie et Gastroentérologie

Matthieu Delaye, Astrid Lièvre, Cindy Neuzillet. Apport de l'immunothérapie dans le traitement des cancers des voies biliaires avancés. Bulletin du Cancer, 2022, 109 (11), pp.11S11-11S20. ⟨10.1016/S0007-4551(22)00464-7⟩. ⟨hal-03930644⟩